Clinical trial · Interventional
Evaluation of Targeted Axillary Lymph Node Dissection in Node Positive Breast Cancer Patients Post Neo Adjuvant Therapy
Evaluation of Targeted Axillary Lymph Nodes Dissection in Node Positive Breast Cancer Patients Post Neo Adjuvant Therapy
NCT05676866CI-TRIAL-00063077unknownPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
evaluation of targeted axillary lymph node dissection in node positive breast cancer patients post neo adjuvant therapy
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Node-positive Breast Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Targeted axillary lymph node dissection | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Breast cancer patients with positive axillary nodes
- description
- Female with invasive breast cancer with axillary metastasis , who recieve neo adjuvant therapy with complete axillary response
- interventionNames
- Procedure: Targeted axillary lymph node dissection
Primary outcomes (2)
- measure
- Evaluation the sensitivity of targeted axillary lymph node dissection in node positive breast cancer patients
- timeFrame
- 3 monthes
- measure
- Comparing sensetivity of targeted axillary dissection with traditional SLND
- timeFrame
- 3 monthes
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 15 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. females with invasive breast cancer with axillary metastasis, staging of n1: n2 2. complete axillary response to neoadjuvant therapy by clinical examination and imaging Exclusion Criteria: * 1\. breast cancer patients who are not candidate for neoadjuvant chemotherapy 2. breast cancer patients with positive axillary node post neoadjuvant chemotherapy 3. breast cancer patients with distant metastasis 4. patients with axillary lymph node metastasis from another primary tumour \[not breast cancer\]
References
Publications (0)
Data not yet available
No reference posted for this study.